01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Truspine Technologies #TSP – Alan Green talks to Chairman Geoff Miller June 7, 2024 – Posted in: Blog, TruSpine Plc (TSP)

Alan Green talks to recently appointed Chairman Geoff Miller following today’s AGM. Geoff explains how he and the board have re-established regular contact with investors and shareholders, and also established a good working relationship with Frank Boehm, the inventor of the IP that underlies the TruSpine offering. Geoff then answers a series of questions from shareholders and investors: he clarifies the IP position, covers the major shareholders and Vela Technologies, and looks at how the…

Continue reading

Truspine #TSP – Company Update November 27, 2023 – Posted in: Blog, TruSpine Plc (TSP)

TruSpine Technologies plc (AQSE: TSP) the medical device company focused on the spinal (vertebral) stabilisation market, provides an update on its business and working capital position. FDA Update  Further to the announcement on 30 October 2023, the Company continues to be in communication with the U.S. Food and Drug Administration (“FDA”) on its 510(k) application for Cervi-LOK as the FDA continue to carry out the substantive review. The Company will update the market on further…

Continue reading

TruSpine #TSP August 2023 – CEO Laurence Strauss talks to Alan Green August 24, 2023 – Posted in: Blog, TruSpine Plc (TSP)

Alan Green talks to Truspine #TSP CEO Laurence Strauss about the developments year to date, and the Company’s recent 510k submission to the US FDA for approval of the Cervi-LOK spinal stabilisation system. Laurence outlines his plans for a US trip to meet with the IP lawyers and the equipment distributors before we discuss the timeframe for future submissions for the other portfolio products GRASP Laminoplasty and Faci-LOK. We then look at the Company funding…

Continue reading

Truspine Technologies #TSP – Further re: FDA Update July 25, 2023 – Posted in: Blog, TruSpine Plc (TSP)

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that, further to the announcement on 1 August 2022, the Company confirms that the FDA 510k submission for Cervi-LOK has been made to the FDA. The FDA’s decision to provide clearance normally takes up to 90 days, following which the Company will be able to commence marketing and sales of Cervi-LOK in the US, if clearance is received from the…

Continue reading

TruSpine #TSP transition – CEO Laurence Strauss talks to Alan Green May 23, 2023 – Posted in: Blog, TruSpine Plc (TSP), Vela Technologies Plc (VELA)

Aquis Exchange listed Truspine Technologies #TSP is both owner and developer of three uniquely disruptive technologies to revolutionise the spinal stabilisation market. These pioneering spinal devices, namely Cervi-LOK™ (for the cervical and upper thoracic spine), GRASP Laminoplasty (a treatment for decompression of the spinal cord) & Faci-LOK™ (for the lumbar and lower thoracic spine) are at various stages of development. Alan Green is joined today by newly appointed CEO Laurence Strauss to discuss his appointment…

Continue reading